Analysis of complete and incomplete response to neoadjuvant therapy in rectum cancer patients
Gastroenterology and Hepatology from Bed to Bench,
Vol. 18 No. Special Issue (2025),
29 December 2025
https://doi.org/10.22037/ghfbb.v18iSpecialIssue.3276
Abstract
Aim: Bioinformatic analysis of the differentially expressed genes (DEGs) of the two groups of patients is the main aim of this project.
Background: Neoadjuvant therapy is a method to treatment disease before local surgery. This method has been administrated to treatment rectum cancer; complete and incomplete responses are observed in patients.
Methods: The DEGs of gene expression profiles of patients with complete and incomplete response to treatment with neoadjuvant therapy were explored from recorded data in Gene Expression Omnibus (GEO) database and evaluated via protein-protein interaction (PPI) analysis and gene ontology assessment.
Results: Among 606 significant DEGs, EGFR, JUN, CDK4, IGF1, and APP were pointed out as the key genes that are involved in response model to neoadjuvant therapy while “GnRH signaling pathway” and “regulation of multicellular organism growth” were introduced as the major involved groups of biological terms.
Conclusion: It can be concluded that, there is genetic variation between rectum cancer patients and efficacy enhancement of treatment need considering precision medicine perspective.
- Gene, neoadjuvant therapy, rectum cancer, bioinformatic
How to Cite
References
1. Trimble EL, Ungerleider RS, Abrams JA, Kaplan RS, Feigal EG, Smith MA, et al. Neoadjuvant therapy in cancer treatment. Cancer. 1993;72(11 Suppl):3515-24.
2. Fowler AM, Mankoff DA, Joe BN. Imaging neoadjuvant therapy response in breast cancer. Radiology. 2017;285(2):358-75.
3. Meredith KL, Weber JM, Turaga KK, Siegel EM, McLoughlin J, Hoffe S, et al. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Annals of surgical oncology. 2010;17(4):1159-67.
4. Biondi A, Persiani R, Cananzi F, Zoccali M, Vigorita V, Tufo A, et al. R0 resection in the treatment of gastric cancer: room for improvement. World journal of gastroenterology: WJG. 2010;16(27):3358.
5. Chatila WK, Kim JK, Walch H, Marco MR, Chen C-T, Wu F, et al. Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer. Nature Medicine. 2022;28(8):1646-55.
6. Alalawy AI. Key genes and molecular mechanisms related to Paclitaxel Resistance. Cancer cell international. 2024;24(1):244.
7. Gu Y, Yang R, Zhang Y, Guo M, Takehiro K, Zhan M, et al. Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer. Molecular Biomedicine. 2025;6(1):2.
8. Zhao P, Zhen H, Zhao H, Huang Y, Cao B. Identification of hub genes and potential molecular mechanisms related to radiotherapy sensitivity in rectal cancer based on multiple datasets. Journal of Translational Medicine. 2023;21(1):176.
9. Amiri-Dashatan N, Koushki M, Ahmadi NA, Ahmadi H, Tavirani MR. Diagnostic and prognostic value of miR-451 expression in colorectal cancer: A Meta-Analysis. Asian Pacific Journal of Cancer Prevention: APJCP. 2024;25(6):1903.
10. Zamanian-Azodi M, Rezaei-Tavirani M, Rahmati-Rad S, Hasanzadeh H, Tavirani MR, Seyyedi SS. Protein-Protein Interaction Network could reveal the relationship between the breast and colon cancer. Gastroenterology and Hepatology from bed to bench. 2015;8(3):215.
11. Mansouri V, Tavirani MR, Tavirani SR. Gene screening of colorectal cancers via network analysis. Gastroenterology and hepatology from bed to bench. 2019;12(2):149.
12. Chong Z, Huang F, McLeod M, Irwin R, Smithson M, Yue Z, et al. Molecular differentiation between complete and incomplete responders to neoadjuvant therapy in rectal cancer. Research Square. 2024:rs. 3. rs-4456000.
13. Herbst RS. Review of epidermal growth factor receptor biology. International Journal of Radiation Oncology* Biology* Physics. 2004;59(2):S21-S6.
14. Tardito S, Matis S, Zocchi MR, Benelli R, Poggi A. Epidermal growth factor receptor targeting in colorectal carcinoma: Antibodies and patient-derived organoids as a smart model to study therapy resistance. International Journal of Molecular Sciences. 2024;25(13):7131.
15. Damare R, Engle K, Kumar G. Targeting epidermal growth factor receptor and its downstream signaling pathways by natural products: A mechanistic insight. Phytotherapy Research. 2024;38(5):2406-47.
16. Sweeney CJ, Hainsworth JD, Bose R, Burris HA, Kurzrock R, Swanton C, et al. MyPathway human epidermal growth factor receptor 2 basket study: pertuzumab+ trastuzumab treatment of a tissue-agnostic cohort of patients with human epidermal growth factor receptor 2–altered advanced solid tumors. Journal of Clinical Oncology. 2024;42(3):258-65.
17. Wang H, Birkenbach M, Hart J. Expression of Jun family members in human colorectal adenocarcinoma. Carcinogenesis. 2000;21(7):1313-7.
18. He L, Shi M, Ren S, Zhang J, Tian Y, Yang X, et al. Jun-APOE-LRP1 axis promotes tumor metastasis in colorectal cancer. Biomolecules and Biomedicine. 2023;23(6):1026.
19. Baker SJ, Reddy EP. CDK4: a key player in the cell cycle, development, and cancer. Genes & cancer. 2012;3(11-12):658-69.
20. Yu M, Wu W, Sun Y, Yan H, Zhang L, Wang Z, et al. FRMD8 targets both CDK4 activation and RB degradation to suppress colon cancer growth. Cell Reports. 2023;42(8).
21. Kasprzak A. Insulin-like growth factor 1 (IGF-1) signaling in glucose metabolism in colorectal cancer. International journal of molecular sciences. 2021;22(12):6434.
22. Guo Y, Nasab EM, Hassanpour F, Athari SS. Linsitinib and aspirin as the IGF1-R antagonists, inhibit regorafenib-resistant chemotherapy in colon cancer. Saudi Journal of Biological Sciences. 2022;29(2):872-7.
23. Meng JY, Kataoka H, Itoh H, Koono M. Amyloid β protein precursor is involved in the growth of human colon carcinoma cell in vitro and in vivo. International Journal of Cancer. 2001;92(1):31-9.
24. da Rocha JF, Bastos L, Domingues SC, Bento AR, Konietzko U, da Cruz E Silva OA, et al. APP binds to the EGFR ligands HB-EGF and EGF, acting synergistically with EGF to promote ERK signaling and neuritogenesis. Molecular neurobiology. 2021;58(2):668-88.
25. Aguilar-Rojas A, Huerta-Reyes M. Human gonadotropin-releasing hormone receptor-activated cellular functions and signaling pathways in extra-pituitary tissues and cancer cells. Oncology reports. 2009;22(5):981-90.
26. Niklas KJ, Newman SA. The origins of multicellular organisms. Evolution & development. 2013;15(1):41-52.
- Abstract Viewed: 92 times
- PDF Downloaded: 46 times